ID
13071
Description
Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00193531
Link
https://clinicaltrials.gov/show/NCT00193531
Keywords
Versions (1)
- 1/14/16 1/14/16 -
Copyright Holder
CC BY-NC 3.0
Uploaded on
January 14, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Neuroendocrine Carcinoma NCT00193531
Eligibility Neuroendocrine Carcinoma NCT00193531
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
age
Data type
boolean
Alias
- UMLS CUI [1]
- C0001779
Description
malignancy
Data type
boolean
Alias
- UMLS CUI [1]
- C0006826
Description
pregnancy
Data type
boolean
Alias
- UMLS CUI [1]
- C0032961
Description
cardiac disease
Data type
boolean
Alias
- UMLS CUI [1]
- C0018799
Description
meningeal metastases
Data type
boolean
Alias
- UMLS CUI [1]
- C0220654
Similar models
Eligibility Neuroendocrine Carcinoma NCT00193531
- StudyEvent: Eligibility